Tivozanib clinical trials
Also written AV-951, KRN951 and Fotivda.
How each study uses tivozanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tivozanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Mar 2021 · FOTIVDA · NDA 212904 (FDA, Drugs@FDA)
- European Union
- 24 Aug 2017 · Fotivda · EMEA/H/C/004131 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2013 (10)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 10 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 15
AVEO Pharmaceuticals, Inc. (22) · Dana-Farber Cancer Institute (3) · Northwestern University (2) · Roswell Park Cancer Institute (2) · Massachusetts General Hospital (2) · M.D. Anderson Cancer Center (1) · Kyowa Kirin Co., Ltd. (1) · Alliance for Clinical Trials in Oncology (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Sorafenib (1) · Atezolizumab (1) · Erlotinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tivozanib.
- Dec 2026Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesPhase 1/2 · University of Florida
Studies
Open first, then newest update. How each study uses tivozanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06661720Written as TivozanibHow we know
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT04645160Written as TivozanibHow we know
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingPhase 1/2University of FloridaNCT05000294Written as TivozanibHow we know
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06053658Written as TivozanibHow we know
- Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedPhase 2Massachusetts General HospitalNCT01885949Written as TivozanibHow we know
- Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedPhase 3AVEO Pharmaceuticals, Inc.NCT04987203Written as TivozanibHow we know
- A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedPhase 3AVEO Pharmaceuticals, Inc.NCT02627963Written as Tivozanib hydrochlorideHow we know
- A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedPhase 1/2AVEO Pharmaceuticals, Inc.NCT03970616Written as TivozanibHow we know
- Tivozanib Before Surgery in Treating Patients With Localized Kidney CancerWithdrawnNot applicableRoswell Park Cancer InstituteNCT01769885Written as tivozanibHow we know
- Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedPhase 1/2AVEO Pharmaceuticals, Inc.NCT03136627Written as TivozanibHow we know
- Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 2Northwestern UniversityNCT01853644Written as TivozanibHow we know
- Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1/2Roswell Park Cancer InstituteNCT01835223Written as Tivozanib (1mg)How we know
- A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedPhase 2AVEO Pharmaceuticals, Inc.NCT01297244Written as TivozanibHow we know
- Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT01745367Written as Tivozanib HydrochlorideHow we know
- A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT01673386Written as TivozanibHow we know
- An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedPhase 3AVEO Pharmaceuticals, Inc.NCT01076010Written as TivozanibHow we know
- A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedPhase 2AVEO Pharmaceuticals, Inc.NCT00502307Written as Tivozanib (AV-951)How we know
- A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsTerminatedNot applicableAVEO Pharmaceuticals, Inc.NCT01369433Written as Tivozanib + paclitaxelHow we know
- A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedPhase 3AVEO Pharmaceuticals, Inc.NCT01030783Written as tivozanib (AV-951)How we know
- A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue SarcomasCompletedPhase 2Northwestern UniversityNCT01782313Written as tivozanibHow we know
See all 38 studies that test tivozanib →
Given beside what is tested · 2 — tivozanib is usual care or a partner of the new treatment
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as TivozanibHow we know
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnPhase 2City of Hope Medical CenterNCT07218692Written as TivozanibHow we know
Codes
What other systems call tivozanib · ClinicalTrials.gg INT005730
- MeSH (NLM) C553176tivozanibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 172030934TTIVOZANIBConfirmed FDA, NLM, Wikidata
- RxNorm 2534233Confirmed FDA, Wikidata
- Wikidata Q7810457tivozanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C85444TivozanibOne source FDA
- DrugBank DB11800One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553176 | tivozanib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 172030934T | TIVOZANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2534233 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7810457 | tivozanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C85444 | Tivozanib | One source FDA |
| DrugBank | DB11800 | — | One source Wikidata |
Also registered as tivozanib hydrochloride (UNII 8A9H4VK35Z · RxNorm 2534245).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.